|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Inflammatory bowel disease surgery in the biologic era显示文摘Anti-tumour necrosis factor(TNF)-α therapy has revolutionized inflammatory bowel disease(IBD) treatment. Infliximab and adalimumab either as monotherapy or in combination with an immunomodulator are able to induce clinical and biological remission in patients with moderate and severe Crohn's disease(CD) and ulcerative colitis(UC). These new therapies have led to a shift in the goals of IBD management from just controlling clinical symptoms to preventing disease progression. However, despite these advances in medical therapy, surgery is still required in 30%-40% of patients with CD and 20%-30% of patients with UC at some point during their lifetime. While biologics certainly play a major role in the medical treatment of IBD, there is concern about the effects of these anti-TNF-α agents on postoperative complications and morbidity. The purpose of this article is to review the role of surgery in the treatment of IBD in the age of biologics and the impact of these medications on per-operative outcomes. In this manuscript we review the relationship between biologic agents and surgery in the treatment of IBD. We also discuss in detail the periopetative risks and complications. | Linda Ferrari Mukta K Krane Alessandro Fichera | 2016 | World Journal of Gastrointestinal Surgery2016，8，5： | 4 |
| 2 | 直肠癌新辅助放化疗和病理完全缓解显示文摘在过去几十年里,直肠癌的治疗已有了很大的进展,其中最为显著的要属20世纪90年代全直肠系膜切除术(TME)的问世和新辅助放化疗(CRT)的应用。临床Ⅰ级证据显示,新辅助放化疗(CRT)可使局部复发率降至6%以下,CRT也就此成为了目前直肠癌的标准治疗模式。CRT可使肿瘤降期,其中15%–27%的患者可以获得病理完全缓解(pCR),意味着CRT后在组织学标本中无任何肿瘤残留。CRT后获得pCR的患者预后良好,局部复发和远处转移风险下降,生存时间延长。因此,积极保留括约肌或保留器官的手术方式如局部切除术在直肠癌治疗中得以更多的应用,甚至非手术治疗也成为可能。尽管多学科综合治疗可使局部进展期直肠癌的局部复发率稳定在5%–6%,但其远处转移率却仍然高达25%以上,这也是患者的主要死因。因此,最近一些研究采用新辅助全量系统化疗以早期治疗远处微转移灶,从而提高肿瘤的系统控制率,仅对化疗无应答者或低位直肠癌(距肛缘不足5 cm)进行术前放疗。 | Linda Ferrari Alessandro Fichera | 2015 | Gastroenterology Report2015，3，4： | 2 |
| 3 | 2011 Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines ? ? The International Consortium for Evidence Based Perfusion formally endorses these guidelines.显示文摘 | Victor A. Ferraris Jeremiah R. Brown George J. Despotis John W. Hammon T. Brett Reece Sibu P. Saha Howard K. Song Ellen R. Clough Linda J. Shore-Lesserson Lawrence T. Goodnough C. David Mazer Aryeh Shander Mark Stafford-Smith Jonathan Waters Robert A. Bak | 2011 | The Annals of Thoracic Surgery2011，，3： | 2 |
| 4 | Hospital Volume, Margin Status, and Long-Term Survival after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma显示文摘 | La Torre Marco Nigri Giuseppe Ferrari Linda Cosenza Giulia Ravaioli Matteo Ramacciato Giovanni | 2012 | EN2012，，2： | 1 |
| 5 | B-cells and mixed cryoglobulinemia显示文摘 | Clodoveo Ferri Alessandro Antonelli Maria Teresa Mascia Marco Sebastiani Poupak Fallahi Daniela Ferrari Marco Giunti Stefano A. Pileri Anna Linda Zignego | 2007 | Autoimmunity Reviews2007，，2： | 1 |
| 6 | B-cells and mixed cryoglobulinemia显示文摘 | Clodoveo Ferri Alessandro Antonelli Maria Teresa Mascia Marco Sebastiani Poupak Fallahi Daniela Ferrari Marco Giunti Stefano A. Pileri Anna Linda Zignego | 2007 | Autoimmunity Reviews2007，，2： | 1 |
| 7 | Development and Validation of a Cardiovascular Risk Assessment Model in Patients With Established Coronary Artery Disease显示文摘 | Linda Battes Rogier Barendse Ewout W. Steyerberg Maarten L. Simoons Jaap W. Deckers Daan Nieboer Michel Bertrand Roberto Ferrari Willem J. Remme Kim Fox Johanna J.M. Takkenberg Eric Boersma Isabella Kardys | 2013 | The American Journal of Cardiology2013，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员